BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/amlx.
What is this all about?
The lawsuit alleges that Amylyx Pharmaceuticals overstated the commercial prospects of its Amyotrophic Lateral Sclerosis ("ALS") treatment Relyvrio and failed to disclose that patients were discontinuing treatment with Relyvrio after six months.
Who is eligible?
Anyone who purchased Amylyx Pharmaceuticals, Inc. stock between ...